Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Juvenile Myelomonocytic Leukemia: early-phase trial registry
5 of 12 indexed Juvenile Myelomonocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 5 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Juvenile Myelomonocytic Leukemia: 12 US clinical trials tracked, 5 recruiting.
Juvenile Myelomonocytic Leukemia is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 4 of these trials.
Enrollment posture brief
Registry condition juvenile-myelomonocytic-leukemia
OPEN 5 | RECR 42% | LATE 2 | EARLY 9 | RANK #1429 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adiposity (42% recruiting · 12 trials)
Juvenile Myelomonocytic Leukemia lists 5 open slots (42% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Juvenile Myelomonocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Juvenile Myelomonocytic Leukemia is recruiting below its size-band peers.
5 of 12 indexed trials (41.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Juvenile Myelomonocytic Leukemia research.
Children's Oncology Group accounts for 4 of 12 trials (33.3%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Juvenile Myelomonocytic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 12 trials that report a genuine target (sentinel values excluded). 10 of those (83.3%) plan for fewer than 100 participants.
-
Juvenile Myelomonocytic Leukemia research is mostly interventional.
12 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU
NCT04726241
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
NCT04024761
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT03810196
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT03326921
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT05800210
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Johns Hopkins All Children's Hospital
NCT03843528
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
National Cancer Institute (NCI)
NCT03190915
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group
NCT01305200
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
NCT01445080
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
NCT00309907
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia
Children's Oncology Group
NCT01824693
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
Children's Oncology Group
NCT00450450
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 4 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Juvenile Myelomonocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Juvenile Myelomonocytic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Juvenile Myelomonocytic Leukemia page
12 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Juvenile Myelomonocytic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Children's Oncology Group sponsors the most Juvenile Myelomonocytic Leukemia trials on record, review their full trial history before evaluating a specific study. See Children's Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Juvenile Myelomonocytic Leukemia condition card totals 12 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.